What works and for whom? Individual patient data meta-analyses in global nutrition research

Christopher R Sudfeld1,2 and Emily R Smith3,4

1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 2Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 3Department of Global Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA; and 4Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA

The seminal paper by Bhutta et al. in the 2008 Lancet Maternal and Child Undernutrition Series addressed the question “What works?” to improve maternal and child survival, health, and nutrition (1). Since then, we have expanded our toolkit of evidence-based interventions that improve child health, growth, and development, including small-quantity lipid-based nutrient supplementation (SQ-LNS) for children (2). Concurrently, there has also been a growing appreciation that the effects of these interventions may differ for individuals and populations. Effect modification or heterogeneity in the magnitude of impact of nutrition interventions in subpopulations of participants with different characteristics may be attributable to various mechanisms such as those related to baseline nutritional deficiency, environmental factors that affect nutrient absorption and storage, sex-specific effects, genetics, and others (3, 4). This concept has also been more broadly recognized through the emergence of “precision public health,” which focuses on “providing the right intervention to the right population at the right time” (5). Accordingly, there is a growing global nutrition literature, including this companion supplement entitled “Lipid-Based Nutrient Supplements,” that expands the original question asked by Bhutta and colleagues to What works and for whom?

Individual patient data (IPD) meta-analyses are considered the “gold standard” for evidence synthesis and analyze original participant data from multiple studies with a consistent quality assessment and statistical approach (6, 7). IPD meta-analyses offer multiple advantages over aggregate study-level data meta-analyses, including greater statistical power and a harmonized approach to assess effect modification (6, 7). Therefore, IPD meta-analyses offer the most robust approach to answer questions about who benefits from interventions. The IPD meta-analyses of child SQ-LNS published in this supplement identified several effect modifiers that would not have been identifiable in study-level analyses—there was a greater effect of child SQ-LNS on stunting, wasting, and other anthropometric measures for girls as compared with boys; on language, motor, and executive function for children in households with low socioeconomic status; and on anemia among children in households with improved water quality (8–11).

Effect modification findings from IPD meta-analyses can give important insight into biological mechanisms, as well as have important program and policy implications. While it is clear based on the aggregate data meta-analysis that child SQ-LNS provided overall beneficial effects on child growth, development, and micronutrient status, the IPD meta-analysis suggests that we should expect the magnitude of SQ-LNS program impacts to vary depending on characteristics of the target population and the outcome of interest (8). Further, programs can also determine the need for targeting interventions to specific populations, address inequalities, or optimize resource utilization given constraints (12). For example, based on the new IPD meta-analyses, a social protection program may consider targeting low-socioeconomic-status households with child SQ-LNS to improve development outcomes (10). In addition, IPD meta-analyses can also address whether subpopulations may experience safety risks. For example, we conducted an IPD meta-analysis on multiple micronutrient supplementation (MMS) in pregnancy that addressed concerns on the safety of MMS for women with short stature; we provided direct evidence that there was no increased risk of adverse outcomes for short stature or any subpopulation of pregnant women (13).

Despite the many strengths of IPD meta-analyses, there are important logistic and methodological limitations to the study design. First, obtaining IPD from each study can be challenging because some investigators may be unwilling or unable to share individual-level data. It is possible that investigators could analyze their own data with a unified statistical approach to provide effect estimates if a 2-stage IPD meta-analytic approach is used. However, while 1-stage (individual-level data pooled in a single dataset and analyzed) and 2-stage approaches for IPD meta-analyses will give the same results when the same modeling assumptions are made, the 1-stage approach offers additional modeling flexibility (14). Further, while IPD meta-analyses allow more thorough investigations of outcomes and subgroups, these analyses also suffer from limitations associated with multiple testing. In the case of investigating heterogeneity, the statistical issue is compounded by the examinations of multiple correlated outcomes across multiple correlated subpopulations of...
interest. For example, in the SQ-LNS IPD meta-analysis on child development outcomes, there were 6 continuous development domain outcomes analyzed by 16 subgroup effect modifiers, which led to 96 statistical tests, of which 13 P values for effect modification were significant at the P < 0.10 level (10). If these tests were fully independent, we would expect ~9 P values <0.10 by chance alone; however, we know that, in this case, the outcomes and modifiers in the analysis were correlated to some degree. Therefore, it is probable that there are false discoveries among the effect modifiers identified in the IPD meta-analyses and advanced statistical methods would be needed to directly address multiple testing of correlated outcomes (15). Regardless, effect modifiers and outcomes should be chosen a priori based on biological plausibility and implementation plans. The possibility of false discovery should be considered an important, if not inherent, limitation to IPD meta-analyses that evaluate multiple outcomes and potential effect modifiers.

Further, there are several methodological innovations that can provide opportunities to ensure timely evidence synthesis. A prospective meta-analysis identifies studies that will contribute data to the meta-analysis, as well as establishes the logistical outcomes and potential effect modifiers. Inherent, limitation to IPD meta-analyses that evaluate multiple false discovery should be considered an important, if not inherent, limitation to IPD meta-analyses that evaluate multiple outcomes and potential effect modifiers.

The authors’ responsibilities were as follows – all authors: read and approved the final manuscript. The authors report no conflicts of interest.

Sponsorship Acknowledgment

This supplement is sponsored by the Institute for Global Nutrition at the University of California, Davis, with funding from the Bill & Melinda Gates Foundation to UC Davis via grant OPP49817.

References

1. Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E, Haider BA, Kirkwood B, Morris SS, Sachdev HP, et al. What works? Interventions for maternal and child undernutrition and survival. Lancet 2008;371(9610):417–40.
2. Victora CG, Christian P, Vidalatti LP, Gatica-Dominguez G, Menon P, Black RE. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. Lancet 2021;397(10282):1388–99.
3. Knol MJ, VanderWeele T. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol 2012;41(2):514–20.
4. Kordas K, Lönnrold B, Stoltzfus RJ. Interactions between nutrition and environmental exposures: effects on health outcomes in women and children. J Nutr 2007;137(12):2794–7.
5. Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. Am J Prev Med 2016;50(3):398–401.
6. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement. JAMA 2015;313(16):1657–65.
7. Tierney JS, Stewart LA, Clarke M. Chapter 26: Individual participant data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions, version 6.2 [Internet] (updated February 2021). London, UK: Cochrane; 2021. Available from: https://training.cochrane.org/handbook/current.
8. Dewey K, Stewart CP, Wessells KR, Prado EL, Arnold CD. Small-quantity lipid-based nutrient supplements for prevention of child malnutrition and promotion of healthy development: overview of individual participant data meta-analysis and programmatic implications. Am J Clin Nutr 2021;114(Suppl 1):3S–14S.
9. Dewey KG, Wessells K, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr 2021;114(Suppl 1):15S–42S.
10. Prado EL, Arnold C, Wessells KR, Stewart CP, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Small-quantity lipid-based nutrient supplements for children age 6-24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. Am J Clin Nutr 2021;114(Suppl 1):43S–67S.
11. Wessells KR, Arnold C, Stewart CP, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr 2021;114(Suppl 1):68S–94S.
12. Christian P, Smith ER, Zaidi A. Addressing inequities in the global burden of maternal undernutrition: the role of targeting. BMJ Global Health 2020;5(3):e002286.
13. Smith ER, Shankar AH, Wu LS, Aboud S, Adu-Afarwuah S, Ali H, Agustina R, Arifeen S, Ashorn P, Bhutta ZA, et al. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. Lancet Global Health 2017;5(11):e1090–100.
14. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36(5):855–75.
15. Jackson D, Riley R, White IR. Multivariate meta-analysis: potential and promise. Stat Med 2011;30(20):2481–98.
16. Burke DL, Eskellie JE, Berndt SJ, Buescher SJ, Rajczak LH, Rogozinskia E, Godolphin PJ, White IR, Parnar MKB. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Med 2021;18(5):e1003629.